Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.
Ho-Jun JangSang-Don ParkHyun Woo ParkJon SuhPyung Chun OhJeonggeun MoonKyounghoon LeeWoong Chol KangSung Woo KwonTae-Hoon KimPublished in: Drugs & aging (2017)
Triple antiplatelet therapy might be a better antiplatelet regimen than dual antiplatelet therapy for patients with ST-segment elevation myocardial infarction. Although this benefit was strong in patients aged <75 years, no definite increase in major bleeding was seen for elderly patients (aged ≥75 years).
Keyphrases
- percutaneous coronary intervention
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute coronary syndrome
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- atrial fibrillation
- end stage renal disease
- coronary artery bypass
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- heart failure
- prognostic factors
- patient reported
- community dwelling